Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Normal B Cells in MBL Exhibit Distinct Transcriptomes Compared to Those of Healthy Individuals, Although They Differ in Activation State Based on IGHV Mutation Status

Gonzalo Blanco, Xiao J. Yan, Anita Ng, Andrew Shih, Jonathan E Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Joanna M. Rhodes, Kanti R. Rai, Nicholas Chiorazzi

Blood (2023) 142 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2023-190901

Published: 2023

Journal Articles

Transcriptomic Analyses Indicate That Pre-Leukemic B Cells from People with Monoclonal B Lymphocytosis Are Surprisingly Much Less Active Than Normal B Cells from People with Monoclonal B Lymphocytosis and from Healthy Donors

Xiao J. Yan, Gonzalo Blanco, Anita Ng, Andrew Shih, Martina Cardillo, Jonathan E Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Joanna M. Rhodes, Kanti R. Rai, Nicholas Chiorazzi

Blood (2023) 142 (Supplement 1): 6512.

https://doi.org/10.1182/blood-2023-191042

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner

Xiao J. Yan, Florencia Palacios, Shih-Shih Chen, Wentian Li, Joanna M. Rhodes, Jacqueline C. Barrientos, Steven L Allen, Jonathan E. Kolitz, Kanti R Rai, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 4125–4126.

https://doi.org/10.1182/blood-2022-170042

Published: 2022

Journal Articles

CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21

Cristina Paraschivescu, Shivani Chhabra, Rukhsana Aslam, Byeongho Jung, Gerardo Ferrer, Jacqueline C. Barrientos, Joanna M. Rhodes, Jonathan E. Kolitz, Steven L Allen, Kanti R Rai, Barbara Sherry, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 7000–7001.

https://doi.org/10.1182/blood-2022-170023

Published: 2022

Journal Articles

CLECL1 + CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment

Shih-Shih Chen, Xiao-Jie Yan, Martina Cardillo, Anita Ng, Andrew Shih, Gonzalo Blanco, Morgan King-Richards, Yu-Ju Chen, Yasmine Kieso, Joanna M. Rhodes, Kanti R Rai, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 1528–1529.

https://doi.org/10.1182/blood-2022-163353

Published: 2022

Journal Articles

Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL

Gonzalo Blanco, Florencia Palacios, Kamala Vanarsa, Poojitha Dugyala, Pui Yan Chiu, Steven L Allen, Yasmine Kieso, Anna Puiggros, Jacqueline C. Barrientos, Xavier Calvo, Jonathan E. Kolitz, Eva Gimeno, Joanna M. Rhodes, Ana Ferrer, Kanti R Rai, Barbara Sherry, Blanca Espinet, Chandra Mohan, Nicholas Chiorazzi

Blood (2022) 140 (Supplement 1): 9859–9861.

https://doi.org/10.1182/blood-2022-169722

Published: 2022

Journal Articles

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Carlos A Lopez, Vernon Wu, Joanna M Rhodes, Kanti R Rai, Jacqueline Barrientos

Blood (2021) 138 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2021-153947

Published: 2021

Journal Articles

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Andrea Nicola Mazzarello, Mark Fitch, Anita Ng, Sabreen Bhuiya, Esha Sharma, Andrew Shih, Martina Cardillo, Steven L Allen, Jonathan E Kolitz, Jacqueline Barrientos, Kanti R Rai, Marc Hellerstein, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2021-154224

Published: 2021

Journal Articles

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

Florencia Palacios, Gonzalo Blanco, Kamala Vanarsa, Poojitha Dugyala, Steven L Allen, Yasmine Kieso, Anna Puiggros, Jacqueline Barrientos, Xavier Calvo, Jonathan E Kolitz, Eva Gimeno, Joanna M Rhodes, ANA Ferrer, Kanti R Rai, Blanca Espinet, Chandra Mohan, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2021-152514

Published: 2021

Journal Articles

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Shih-Shih Chen, Jacqueline Barrientos, Xiao-Jie Yan, Uwe Wirtz, Edith Szafer-Glusman, Kanti R Rai, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2021-153685

Published: 2021

Journal Articles

AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms

Blood (2021) 138 (3): 246–258.

https://doi.org/10.1182/blood.2020008654

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Blood (2021) 137 (20): 2817–2826.

https://doi.org/10.1182/blood.2020007376

Published: 2021

Includes: Supplemental data

Journal Articles

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Xavier Calvo, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3027.

https://doi.org/10.1182/blood-2019-122038

Published: 2019

Journal Articles

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Xavier Calvo, MD PhD, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3029.

https://doi.org/10.1182/blood-2019-122061

Published: 2019

Journal Articles

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Shih-Shih Chen, PhD, Constantine S. Tam, MBBS (Hons), MD, Alan G. Ramsay, BSc,MSc,PhD, Priyadarshini Ravichandran, Natalia C. Couto-Francisco, Michael Ibrahim, Gerardo Ferrer, PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, He Zhou, Jacqueline C Barrientos, MD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2019) 134 (Supplement_1): 477.

https://doi.org/10.1182/blood-2019-127255

Published: 2019

Journal Articles

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Blood (2019) 134 (8): 688–698.

https://doi.org/10.1182/blood.2019000490

Published: 2019

Includes: Supplemental data

Journal Articles

Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo

Andrea Nicola Mazzarello, PhD, Marcus Dühren-von Minden, PhD, Eva Gentner, BSc, MSc, PhD, Palash Chandra Maity, PhD, Gerardo Ferrer, PhD, Tatyana Tarasenko, Stefano Vergani, PhD, Jacqueline C Barrientos, MD MS, Kanti R Rai, MD, Peter McGuire, Hassan Jumaa, PhD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2018-99-119989

Published: 2018

Journal Articles

Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue

Rukhsana Aslam, MD, Jacqueline C Barrientos, MD MS, Gerardo Ferrer, PhD, Pui Yan Chiu, Kanti R Rai, MD, Nicholas Chiorazzi, MD, Barbara Sherry, PhD

Blood (2018) 132 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2018-99-116910

Published: 2018

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

NARROW

Normal B Cells in MBL Exhibit Distinct Transcriptomes Compared to Those of Healthy Individuals, Although They Differ in Activation State Based on IGHV Mutation Status

Transcriptomic Analyses Indicate That Pre-Leukemic B Cells from People with Monoclonal B Lymphocytosis Are Surprisingly Much Less Active Than Normal B Cells from People with Monoclonal B Lymphocytosis and from Healthy Donors

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner

CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21

CLECL1 + CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment

Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo

Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only